Glycogen storage disease type V – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:29:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Glycogen storage disease type V – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of EDG-5506 in Adults with Becker Muscular Dystrophy, McArdle Disease, or Limb-Girdle Muscular Dystrophy https://clinicaltrials.eu/trial/study-on-the-effects-of-edg-5506-in-adults-with-becker-muscular-dystrophy-mcardle-disease-or-limb-girdle-muscular-dystrophy/ Wed, 29 Apr 2026 14:25:09 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-edg-5506-in-adults-with-becker-muscular-dystrophy-mcardle-disease-or-limb-girdle-muscular-dystrophy/ This clinical trial is focused on studying the effects of a new treatment called EDG-5506 on certain muscle-related diseases. The diseases being studied are Becker Muscular Dystrophy, McArdle Disease, and Limb-Girdle Muscular Dystrophy. These are conditions that affect the muscles, leading to weakness and other symptoms. The treatment being tested, EDG-5506, is taken in the form of a tablet.

The purpose of the study is to understand how EDG-5506 affects markers in the body that indicate muscle damage. Participants in the study will be randomly assigned to receive either the EDG-5506 tablet or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure the results are unbiased.

Throughout the study, participants will undergo various assessments to monitor their health and the effects of the treatment. These assessments will include checking for any side effects, measuring changes in muscle-related markers, and evaluating overall health through tests like blood work and physical exams. The study will last for a period of time, during which participants will be closely monitored to gather important information about the safety and effectiveness of EDG-5506.

]]>